MOUNTAIN VIEW,
Calif., Feb. 8, 2012
/PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today
announced that the Company will participate in the following
investor conferences in February
2012:
Leerink Swann 2012 Global Healthcare
Conference
Thursday, February 16, at
11:30 a.m. ET in New York
2012 Citi Global Healthcare
Conference
Tuesday, February 28, at 8:00 a.m. ET in New
York
A live webcast of each event will be
available on the Investor Relations section of MAP Pharmaceuticals'
website at http://www.mappharma.com. A replay also will be
available within 24 hours for seven days following each
presentation.
About MAP Pharmaceuticals
MAP Pharmaceuticals is a
biopharmaceutical company focused on developing and commercializing
new therapies to address undermet patient needs in neurology.
The Company is developing LEVADEX®, an orally inhaled
investigational drug for the acute treatment of migraine. The New
Drug Application for LEVADEX is currently under review by the U.S.
Food and Drug Administration. MAP Pharmaceuticals has entered
into a collaboration agreement with Allergan, Inc. to co-promote
LEVADEX to neurologists and pain specialists in the U.S. and
Canada. The Company also applies
its proprietary drug particle and inhalation technologies to
generate new pipeline opportunities by enhancing the therapeutic
benefits of proven drugs, while minimizing risk by capitalizing on
their known safety, efficacy and commercialization history.
Additional information about MAP Pharmaceuticals can be found at
http://www.mappharma.com.
CONTACT:
Lisa Borland
MAP Pharmaceuticals, Inc.
650-386-3122
lborland@mappharma.com
SOURCE MAP Pharmaceuticals, Inc.